| pubmed-article:21502577 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0948089 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0039082 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:21502577 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:21502577 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:21502577 | pubmed:dateCreated | 2011-5-3 | lld:pubmed |
| pubmed-article:21502577 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:abstractText | Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling. The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS. | lld:pubmed |
| pubmed-article:21502577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21502577 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21502577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502577 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21502577 | pubmed:month | May | lld:pubmed |
| pubmed-article:21502577 | pubmed:issn | 1524-4539 | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:BhattDeepak... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:FitzgeraldDes... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:ZeymerUweU | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:GoodmanShaun... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:AngiolilloDom... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:GotoShinyaS | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:ContantCharle... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:AylwardPhilip... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:DudekDariuszD | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:GuettaVictorV | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:FlatherMarcus... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:MontalescotGi... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:DAROH JHJ | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:WiviottStephe... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:O'DonoghueMic... | lld:pubmed |
| pubmed-article:21502577 | pubmed:author | pubmed-author:ZiecinaRafalR | lld:pubmed |
| pubmed-article:21502577 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21502577 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:21502577 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:21502577 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21502577 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21502577 | pubmed:pagination | 1843-53 | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:meshHeading | pubmed-meshheading:21502577... | lld:pubmed |
| pubmed-article:21502577 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21502577 | pubmed:articleTitle | Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. | lld:pubmed |
| pubmed-article:21502577 | pubmed:affiliation | Brigham and Women's Hospital, Boston, MA 02115, USA. modonoghue@partners.org | lld:pubmed |
| pubmed-article:21502577 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21502577 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21502577 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21502577 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21502577 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21502577 | lld:pubmed |
